Article Correctness Is Author's Responsibility: Drug used for ******, kidney cancers may also extend survival for head and neck cancers

(American Society for Radiation Oncology) A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo, and the benefit persisted for those with mutations in their TP53 gene.